Pricing

Aptose Biosciences Inc (APTO)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
William G. Rice
Employees:
40
251 CONSUMERS ROAD, SUITE 1105, TORONTO, A6, M2J 4R3
647-479-9828
    Formally known as:
  • APTOSE BIOSCIENCES, INC. ORDINARY
  • APTOSE BIOSCIENCES, INC. ORDINARY
  • Lorus Therapeutics, Inc.
Stock Split History
DateRatio
2010-06-01 1:3
2014-10-06 1:12
Aptose Biosciences discovers and develops personalized therapies addressing unmet medical needs in oncology. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and HR MDS. The company also develops luxeptinib, a dual bromodomain and extra-terminal domain motif motif motif protein and kinase inhibitor program.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available